None of the reports to date on PASS have described systematically the hospital disposition among survivors or their long-term clinical course. Further studies are urgently needed to CYT387 better understand the post-hospitalization outcomes of survivors of maternal severe sepsis, to

better address prevention and need for long-term care interventions. Conclusion PASS is a rare, but likely rising complication in some developed countries, while there is lack of data on its occurrence in developing countries. PASS has been infrequently described and multiple methodological limitations affect the interpretation of the varying epidemiological, clinical, resource utilization and outcome characteristics described by investigators to date. PASS is more likely to develop among minority women, the uninsured, those with chronic illness, and following invasive interventions. The genital tract is the most common reported site of infection. However, other, non-obstetric, sites of infection should be considered, though the site of infection may often not be readily apparent. Although the reported case fatality is lower compared with the general population

with severe sepsis, PASS can be rapidly fatal. Because of the overlap between some of the early clinical manifestations of PASS and those of normal pregnancy-related physiological changes, and the rarity of Saracatinib research buy this condition, high level of clinicians’ vigilance is crucial for assuring early recognition and timely intervention. Future studies are urgently needed to better understand the burden of PASS across the spectrum of pregnancy outcomes, in both developed and developing countries, to improve systemic

approach to PRN1371 assure effective care, and for improved insight into its long-term sequelae. Acknowledgments No funding or sponsorship was received for this study or publication of this article. The author meets the ICMJE criteria for authorship for this manuscript, takes responsibility for the integrity of the work as whole and has given final approval for the version published. Conflict of interest Lavi Oud declares no conflict of interest. Compliance with ethics guidelines Because we review publicly reported data, Etofibrate this study is exempt from formal review by the Texas Tech Health Sciences Center Institutional Review Board. This article does not involve any new studies with human or animal subjects performed by the author. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. Electronic supplementary material Below is the link to the electronic supplementary material.